LYMPHANGIOLEIOMYOMATOSIS (LAM)
Clinical trials for LYMPHANGIOLEIOMYOMATOSIS (LAM) explained in plain language.
Never miss a new study
Get alerted when new LYMPHANGIOLEIOMYOMATOSIS (LAM) trials appear
Sign up with your email to follow new studies for LYMPHANGIOLEIOMYOMATOSIS (LAM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Leukemia drug tested for rare lung disease in new safety trial
Disease control Recruiting nowThis study is testing the long-term safety of a drug called imatinib in people with a rare lung disease called LAM. Imatinib is already approved for leukemia, and early research suggests it might kill LAM cells. The trial will enroll 20 women with LAM to take either imatinib or a…
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Phase: PHASE1 • Sponsor: Columbia University • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Scientists hunt for blood clues to track rare lung disease
Knowledge-focused Recruiting nowThis study aims to understand if tiny particles in the blood, called extracellular vesicles, can serve as useful markers for a rare lung disease called LAM. Researchers will collect blood samples and health data from 80 women with LAM, a related condition called TSC, and healthy …
Matched conditions: LYMPHANGIOLEIOMYOMATOSIS (LAM)
Sponsor: University of Milan • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC